A. Yadav, Suman Gnawali, S. Mandal, Gyaneswhor Shrestha, G. Yuan
{"title":"mRNA COVID-19 vaccine: A future hope for cancer treatment","authors":"A. Yadav, Suman Gnawali, S. Mandal, Gyaneswhor Shrestha, G. Yuan","doi":"10.3126/jbs.v8i2.41959","DOIUrl":null,"url":null,"abstract":"Background: mRNA vaccines have a strong potential for a possible cancer therapy platform. They express tumor antigens in antigen-presenting cells (APCs) after immunization, facilitating innate/adaptive immune stimulation. Because of its high effectiveness, safe administration, rapid development potential, and cost-efficient manufacturing, the mRNA cancer vaccine surpasses other traditional vaccination platforms. \nConclusion: Careful evaluation of promising mRNA vaccines to supervise as carriers of lipids for cancer patients needs to be done. In addition, a possible revaluation for optimal protection is required. However, the extent to which solid tumours might take a significant part of the vaccine doses is still unknown. ","PeriodicalId":7690,"journal":{"name":"American Journal of Biomedical Sciences","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2021-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"American Journal of Biomedical Sciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3126/jbs.v8i2.41959","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1
Abstract
Background: mRNA vaccines have a strong potential for a possible cancer therapy platform. They express tumor antigens in antigen-presenting cells (APCs) after immunization, facilitating innate/adaptive immune stimulation. Because of its high effectiveness, safe administration, rapid development potential, and cost-efficient manufacturing, the mRNA cancer vaccine surpasses other traditional vaccination platforms.
Conclusion: Careful evaluation of promising mRNA vaccines to supervise as carriers of lipids for cancer patients needs to be done. In addition, a possible revaluation for optimal protection is required. However, the extent to which solid tumours might take a significant part of the vaccine doses is still unknown.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
